Nirvana Life Sciences Inc.
NIRVF
$0.08
-$0.01-8.07%
OTC PK
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 72.46% | -72.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.46% | -70.04% | |||
| Operating Income | -72.46% | 70.04% | |||
| Income Before Tax | -147.17% | 77.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -147.17% | 77.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 100.00% | |||
| Net Income | -147.17% | 77.84% | |||
| EBIT | -72.46% | 70.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -141.67% | 95.16% | |||
| Normalized Basic EPS | -80.00% | 93.55% | |||
| EPS Diluted | -141.67% | 95.16% | |||
| Normalized Diluted EPS | -80.00% | 93.55% | |||
| Average Basic Shares Outstanding | 0.48% | 373.19% | |||
| Average Diluted Shares Outstanding | 0.48% | 373.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||